Patients with peritoneal mesothelioma lack epidermal growth factor receptor tyrosine kinase mutations that would make them sensitive to tyrosine kinase inhibitors

Oncology Reports

Volumn 27, Issue 6, 2012, Pages 1794-1800

  Kalra, Neetu ^a   Ashai, Ali ^a   Xi, Liqiang ^a   Zhang, Jingli ^a   Avital, Itzhak ^a   Raffeld, Mark ^a   Hassan, Raffit ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

EGFR; Erlotinib; Peritoneal mesothelioma; Somatic mutation; Tyrosine kinase inhibitor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; ERLOTINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; EGFR GENE; FEMALE; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HUMAN; HUMAN CELL; MALE; PERITONEUM CELL; PERITONEUM MESOTHELIOMA; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SOMATIC MUTATION; TUMOR GENE;

ADENOCARCINOMA; ADULT; AGED; CELL LINE, TUMOR; FEMALE; GENES, ERBB-1; HUMANS; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; MUTATION; PERITONEAL NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84860731129     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1725     Document Type: Article

References (28)

1. Robinson BW and Lake RA: Advances in malignant mesothelioma. N Engl J Med 353: 1591-1603, 2005. (Pubitemid 41434638)
2. Price B and Ware A: Time trend of mesothelioma incidence in the United States and projection of future cases: an update based on SEER data for 1973 through 2005. Crit Rev Toxicol 39: 576-588, 2009.
3. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, et al: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21: 2636-2644, 2003. (Pubitemid 46606305)
4. Yan TD, Deraco M, Baratti D, Kusamura S, Elias D, Glehen O, Gilly FN, Levine EA, Shen P, Mohamed F, et al: Cytoreductive surgery and hypothermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol 27: 6237-6242, 2009.
5. Baratti D, Kusamura S and Deraco M: Diffuse malignant peritoneal mesothelioma: systematic review of clinical management and biological research. J Surg Oncol 103: 822-831, 2011.
6. Mitsudomi T and Yatabe Y: Epidermal growth receptor in relation to tumor development EGFR gene and cancer. FEBS J 277: 301-308, 2010.
7. Arteaga CL: Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 7: 31-39, 2002.
8. Destro A, Ceresoli GL, Falleni M, Zucali PA, Morenghi E, Bianchi P, Pellegrini C, Cordani N, Vaira V, Alloisio M, et al: EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations. Lung Cancer 51: 207-215, 2006. (Pubitemid 43144364)
9. Trupiano JK, Geisinger KR, Willingham MC, Manders P, Zbieranski N, Case D and Levine EA: Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markers. Mod Pathol 17: 476-481, 2004. (Pubitemid 41646604)
10. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, et al: National Cancer Institute of Canada Clinical Trials Group: Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 353: 123-132, 2005.
11. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139, 2004. (Pubitemid 38637993)
12. Gazdar AF, Shigematsu H, Herz J and Minna JD: Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers? Trends Mol Med 10: 481-486, 2004. (Pubitemid 39303620)
13. Cortese JF, Gowda AL, Wali A, Eliason JF, Pass HI and Everson RB: Common EGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma. Int J Cancer 118: 521-522, 2006. (Pubitemid 41779097)
14. Okuda K, Sasaki H, Kawano O, Yukiue H, Yokoyama T, Yano M and Fujii Y: Epidermal growth factor receptor gene mutation, amplification and protein expression in malignant pleural mesothelioma. J Cancer Res Clin Oncol 134: 1105-1111, 2008.
15. Govindan R, Kratzke RA, Herndon JE II, Niehans GA, Vollmer R, Watson D, Green MR and Kindler HL: Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res 11: 2300-2304, 2005. (Pubitemid 40490190)
16. Garland LL, Rankin C, Gandara DR, Rivkin SE, Scott KM, Nagle RB, Klein-Szanto AJ, Testa JR, Altomare DA and Borden EC: Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J Clin Oncol 25: 2406-2413, 2007. (Pubitemid 46999211)
17. Foster JM, Gatalica Z, Lilleberg S, Haynatzki G and Loggie BW: Novel and existing mutations in the tyrosine kinase domain of the epidermal growth factor receptor are predictors of optimal respectability in a malignant peritoneal mesothelioma. Ann Surg Oncol 16: 152-158, 2009.
18. Foster JM, Radhakrishna U, Govindarajan V, Carreau JH, Gatalica Z, Sharma P, Nath SK and Loggie BW: Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma. World J Surg Oncol 8: 88, 2010.
19. Liu Z, Liu L, Li M, Wang Z, Feng L, Zhang Q, Cheng S and Lu S: Epidermal growth factor receptor mutation in gastric cancer. Pathology 43: 234-238, 2011.
20. Jia XL and Chen G: EGFR and KRAS mutations in Chinese patients with adenosquamous carcinoma of the lung. Lung Cancer 74: 396-400, 2011.
21. Longatto-Filho A, Pinheiro C, Martinho O, Moreira MA, Ribeiro LF, Queiroz GS, Schmitt FC, Baltazar F and Reis RM: Molecular characterization of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinoma. BMC Cancer 9: 212, 2009.
22. Tzeng CW, Frolov A, Frolova N, Jhala NC, Howard JH, Buchsbaum DJ, Vickers SM, Heslin MJ and Arnoletti JP: Epidermal growth factor receptor (EGFR) is highly conserved in pancreatic cancer. Surgery 141: 464-469, 2007. (Pubitemid 46441307)
23. Naji F, Attaleb M, Laantri N, Benchakroun N, El Gueddari B, Benider A, Azeddoug H, Ennaji MM, El Mzibri M and Khyatti M: Identification of G2607A mutation in EGFR gene with a significative rate in Moroccan patients with nasopharyngeal carcinoma. Cell Mol Biol (Noisy-le-grand) 56 (Suppl): OL1442-OL1426, 2010.
24. Zhang W, Stabile LP, Keohavong P, Romkes M, Grandis J, Traynor AM and Siegfried JM: Mutation and polymorphism in the EGFR-TK domain associated with lung cancer. J Thorac Oncol 1: 635-647, 2006. (Pubitemid 47163950)
25. Taguchi T, Tsukuda M, Imagawa-Ishiguro Y, Kato Y and Sano D: Involvement of EGFR in the response of squamous cell carcinoma of the head and neck cell lines to gefitinib. Oncol Rep 19: 65-71, 2008. (Pubitemid 351176132)
26. Sasaki H, Endo K, Takada M, Kawahara M, Tanaka H, Kitahara N, Matsumura A, Iuchi K, Kawaguchi T, Okuda K, et al: EGFR polymorphism of the kinase domain in Japanese lung cancer. J Surg Res 148: 260-263, 2008.
27. Yang CH, Yu CJ, Shih JY, Chang YC, Hu FC, Tsai MC, Chen KY, Lin ZZ, Huang CJ, Shun CT, et al: Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy. J Clin Oncol 26: 2745-2753, 2008.
28. Perrone F, Jocollè G, Pennati M, Deraco M, Baratti D, Brich S, Orsenigo M, Tarantino E, De Marco C, Bertan C, et al: Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma. Eur J Cancer 46: 2837-2848, 2010.